Indication: For treatment (together with surgery or LHRH analogue) of advanced prostatic cancer.
Pharmacology: Bicalutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Bicalutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Bicalutamide blocks the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
Mechanism Of Action: Bicalutamide competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue.
Absorption: Bicalutamide is well-absorbed following oral administration, although the absolute bioavailability is unknown.
Interactions:
DrugBank: Interactions for Bicalutamide
Interactions for Bicalutamide:
In vitro studies have shown CASODEX can displace coumarin anticoagulants, such as warfarin, from their
protein-binding sites. It is recommended that if CASODEX is started in patients already receiving coumarin
anticoagulants, prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be
necessary.
Chemical IUPAC Name: N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methyl-propanamide
Chemical Formula: C18H14F4N2O4S
Half Life: 5.9 days
Drug Type: Approved Drug
# Accession No: APRD00042
CAS Registry Number: 90357-06-5
Bicalutamide News (When available)
Prostate Cancer: New choice for hormone refractory patientsDec 8, 2005 PharmaLive.com (press release), LONDON, December 8, 2005- While the use of AstraZeneca’s bicalutamide monotherapy in prostate cancer continues, its use has significantly decreased in ...
AstraZeneca's Casodex may get boostDec 8, 2005 Science Daily (press release) ..."This will be especially important in the (United States), as certain oral medications including bicalutamide (Casodex) are expected to be reimbursable under ...
New Data Show Survival Benefit for Arimidex(TM) in Early Breast ...Dec 9, 2005 news aktuell (Pressemitteilung), ...oncology that led to the development of its current anti-cancer therapies including 'ARIMIDEX' (anastrozole), 'CASODEX' (bicalutamide), 'FASLODEX' (fulvestrant ...
Merck, Gilead in integrase-inhibitor raceJan 13, 2006 Science Daily (press release) AstraZeneca's Casodex may get boost (December 8, 2005) -- A new analysis of the Early Prostate Cancer trial may restore physician confidence in AstraZeneca's ...
AstraZeneca set to acquire first brand soonDec 14, 2005 Sify, The weeks-old entrants are Casodex for prostate cancer and Iressa for lung cancer, which means five of the parent company's seven oncology brands have now come ...
Home
Copyright phasechange.org 2006.
All Rights Reserved.
